Endo buying NuPathe for $105m to launch Zecuity in 2014
This article was originally published in Scrip
Executive Summary
Endo Health Solutions will pay $105m in cash for NuPathe and plans to launch the transdermal migraine drug Zecuity during the first half of 2014.